


1fw

Attorney Docket No.: 6568.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: Conde-Frieboes et al.

Serial No.: 10/719,110

Group Art Unit: To be assigned

Filed: November 21, 2003

Examiner: To be assigned

For: Compounds and Compositions for Treating Obesity

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **August 19, 2004**

Csaba Attila Szakolczai
(name of person mailing paper)

Csaba Attila Szakolczai
(signature of person mailing paper)



Attorney Docket No.: 6568.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Conde-Frieboes et al.

Application No.: 10/719,110

Group Art Unit: To be assigned

Filed: November 21, 2003

Examiner: To be assigned

For: Compounds and Compositions for Treating Obesity

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. The Following references were included in an Information Disclosure Statement filed for the above-captioned application on January 20, 2004:

1. Huszar et al., Cell, Vol. 88, pp. 131-41 (1997)
2. Klebig et al., Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 4728-32 (1995)
3. Vaisse et al., Nature Genetics, Vol. 20, pp. 113-4 (1998)
4. Vergoni et al., European J. of Pharma., Vol. 179, pp. 347-55 (1990)
5. Yeo et al., Nature Genetics, Vol. 20, pp. 111-2 (1998)

A copy of the new references for the above-captioned application is enclosed.


The references are as follows:

1. WO 02/059107 A1
2. WO 97/48685
3. WO 02/070493 A1
4. WO 01/81321 A1
5. Veerman et al., J. Org. Chem., Vol. 68, pp. 4486-94 (2003)
6. Arasasingham et al., J. Med. Chem., Vol. 46, pp. 9-11 (2003)
7. Dyck et al., Bioorg Med. Chem. Letter, Vol. 13, pp. 3793-96 (2003)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: August 19, 2004

Respectfully submitted,


Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Group To be assigned

[illegible][illegible]

OTHER DOCUMENTS (including Author, Title, Date, Volume, Page, etc.)			
			Veerman et al., J. Org. Chem., Vol. 68, pp. 4486-94 (2003)
			Arasasingham et al., J. Med. Chem., Vol. 46, pp. 9-11 (2003)
			Dyck et al., Bioorg Med. Chem. Letter, Vol. 13, pp. 3793-96 (2003)
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.